Adagene Inc

Adagene Inc. is a clinical-stage biotechnology company that researches, develops, and produces monoclonal antibody drugs for cancer in the People's Republic of China. Its lead candidate, ADG126, is a masked fully-human anti-CTLA-4 monoclonal antibody in phase 1b/2 clinical development for cancer treatment. The company also develops ADG116, ADG206, ADG104, and ADG125, as well as preclinical candidates ADG138, ADG152, ADG153, and CD28 T-cell engagers. Incorporated in 2011, Adagene is headquartered in Suzhou, China.